Valence8 US LP Buys New Position in Indivior PLC (NASDAQ:INDV)

Valence8 US LP acquired a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 57,293 shares of the company's stock, valued at approximately $564,000. Indivior comprises approximately 0.2% of Valence8 US LP's portfolio, making the stock its 18th largest holding.

A number of other institutional investors and hedge funds have also bought and sold shares of INDV. Millennium Management LLC increased its stake in shares of Indivior by 48.1% in the second quarter. Millennium Management LLC now owns 493,313 shares of the company's stock valued at $7,952,000 after buying an additional 160,282 shares during the period. Janus Henderson Group PLC boosted its position in Indivior by 14.2% during the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company's stock valued at $9,424,000 after acquiring an additional 54,750 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in Indivior during the 3rd quarter worth about $2,364,000. Susquehanna International Group Ltd. acquired a new position in shares of Indivior in the 2nd quarter valued at about $3,224,000. Finally, Mediolanum International Funds Ltd bought a new stake in shares of Indivior during the 3rd quarter valued at about $1,240,000. Institutional investors and hedge funds own 60.33% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 price objective (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th. Craig Hallum decreased their price target on shares of Indivior from $20.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, October 11th.

Indivior Stock Up 0.2 %

Shares of INDV traded up $0.02 on Friday, reaching $10.78. The company's stock had a trading volume of 423,076 shares, compared to its average volume of 517,976. The stock has a market capitalization of $1.49 billion, a PE ratio of -268.93 and a beta of 0.70. The company has a current ratio of 0.83, a quick ratio of 0.65 and a debt-to-equity ratio of 23.50. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $23.22. The firm has a fifty day moving average of $9.45 and a 200-day moving average of $12.64.

Indivior (NASDAQ:INDV - Get Free Report) last posted its earnings results on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The company had revenue of $307.00 million for the quarter, compared to analyst estimates of $302.25 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. Equities analysts predict that Indivior PLC will post 1.66 EPS for the current year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.